PERKINELMER INC Stock Price, News & Analysis

PerkinElmer (NYSE: PKI) has announced an agreement to acquire BioLegend for approximately $5.25 billion in cash and stock, marking the largest transaction in PerkinElmer’s history. This strategic acquisition aims to enhance PerkinElmer’s life science offerings, particularly in high-growth areas like proteogenomics and cell separation. BioLegend is expected to generate around $380 million in revenue for 2022 and will transition into PerkinElmer’s Center of Excellence for research reagents. The deal anticipates earnings accretion of $0.30 per share in the first year.

PerkinElmer, Inc. (NYSE: PKI) announced a quarterly dividend of $0.07 per share on July 23, 2021. The dividend is scheduled for payment on November 12, 2021, to shareholders of record as of October 22, 2021. PerkinElmer reported a revenue of approximately $3.8 billion in 2020 and employs around 14,000 people across 190 countries. The company is also included in the S&P 500 Index.

PerkinElmer (NYSE: PKI) announced it expects to exceed its financial guidance for Q2 ending July 4, 2021, driven by strong performance in both COVID and non-COVID sectors. A Virtual Investor and Analyst Day is set for today, featuring presentations from key executives. The company will release its Q2 financial results after market close on July 28, followed by a conference call at 5:00 p.m. ET the same day. In 2020, PerkinElmer reported approximately $3.8 billion in revenue and employs over 14,000 people globally.

PerkinElmer (NYSE: PKI) has announced its agreement to acquire SIRION Biotech GmbH, a leader in viral vector-based technologies essential for cell and gene therapies. The transaction is expected to conclude in Q3 2021. With SIRION's innovative offerings, PerkinElmer aims to enhance its Horizon Discovery portfolio, which already includes advanced gene editing tools. This acquisition aligns with the growing demand for viral vector approaches in gene therapy, particularly in treating diseases like cancer.

Oxford Immunotec, part of PerkinElmer, announced its T-SPOT® Discovery SARS-CoV-2 kit is utilized in the UK COVID-19 Human Challenge Study. This national collaboration aims to expedite vaccine development against COVID-19 by identifying effective viral doses in a controlled setting. The study began in March 2021, focusing on analyzing immune responses, particularly T cell reactions. The T-SPOT technology is employed to enhance understanding of immune responses, thus aiding future vaccine efficacy studies. The kit is currently for research use only.

PerkinElmer (NYSE: PKI) has agreed to acquire Immunodiagnostic Systems Holdings PLC (LSE: IHS) for about $155 million (£110 million), enhancing its diagnostics capabilities, particularly in immunodiagnostics. The deal, with an enterprise value of approximately $124 million (£88 million), is expected to close by early Q3 2021, pending shareholder and court approvals. This acquisition will integrate IDS's chemiluminescence products with PerkinElmer's offerings, creating synergies and expanding their global presence in key diagnostic markets.

PerkinElmer, Inc. (NYSE: PKI) has announced its agreement to acquire Nexcelom Bioscience for $260 million in cash, expected to close in Q2 2021. Nexcelom specializes in automated cell counting instruments and cytometry, generating approximately $40 million in 2021 revenues. This acquisition aims to enhance PerkinElmer's drug discovery solutions and streamline workflows for clients in academia and biopharmaceuticals. The deal follows PerkinElmer's recent acquisition of Horizon Discovery, indicating a strong push towards expanding capabilities in life sciences.

Oxford Immunotec, part of PerkinElmer, announced that its T-SPOT^®.COVID test will be utilized in the COV-AD study, collaborating with the University of Birmingham. This study aims to monitor the SARS-CoV-2 infection and immune responses in patients with antibody deficiencies. Conducted across 13 UK sites, it seeks to determine the outcomes of COVID-19 in immunodeficient patients by assessing their T cell responses and antibody levels. The results could inform vaccination strategies and improve the understanding of immunity in vulnerable populations.

PerkinElmer, a leading global innovator, is hosting a virtual Investor and Analyst Day on June 24, 2021, from 8:30 a.m. to 12:00 p.m. ET. This event will feature key presentations from the senior management team, including updates on current business conditions. Registered attendees can access a live webcast through the Investors section of the company's website. A replay will also be available post-event. In 2020, PerkinElmer reported revenues of approximately $3.8 billion and employs over 14,000 people globally.